TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children With ADHD
Brief Summary: The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with attention deficit hyperactivity disorder (ADHD), when compared to placebo.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CONCERTA (methylphenidate HCl) / Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Placebo/ CONCERTA (methylphenidate HCl) | Intervention Type: DRUG; Name: Placebo/ CONCERTA (methylphenidate HCl); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CONCERTA (methylphenidate HCl) / Placebo; Assigned to Arm(s): 1
B: Arm Label: HLD200 (methylphenidate); Type: EXPERIMENTAL; Interventions: Drug: HLD200 methylphenidate hydrochloride (MPH) Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HLD200 methylphenidate hydrochloride (MPH) Capsules; Assigned to Arm(s): HLD200 (methylphenidate) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Lisdexamfetamine dimesylate; Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine dimesylate | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine dimesylate; Assigned to Arm(s): Lisdexamfetamine dimesylate | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Pycnogenol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Pycnogenol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Intervention Type: DIETARY_SUPPLEMENT; Name: Pycnogenol; Assigned to Arm(s): Pycnogenol | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Combination Therapy With Oseltamivir and Zanamivir Versus Monotherapy in the Treatment of Virologically Confirmed Influenza in Primary Care a Randomises Double Blind Controlled Trial Study
Brief Summary: In order to prevent the high mortality due to an hypothetic pandemic caused by a newly emerging influenza A virus, antiviral drugs are seen as essential requirements for control of initial influenza outbreaks.Two antivirals are available for the treatment oseltamivir and zanamivir. Emergence of Oseltamivir resistance has been recently reported. . It appeared opportune to assess the efficacy and safety of biotherapy of neuraminidase inhibitors ,will be investigated by a randomized, placebo controlled, double blind study in France, during the next winter season . This study will be conducted in 300 centres of primary care with 900 adults with a virologically suspected influenza A infection. Individuals will be randomized to 1 of the 3 treatment groups: oseltamivir +zanamivir, or oseltamivir+placebo or placebo +zanamivir.The primary judgment criteria will be the proportion of patients with negative RT PCR negative in nasal secretions at Day 2.


Options:
A: Arm Label: Pegcetacoplan; Type: EXPERIMENTAL; Interventions: Drug: Pegcetacoplan, Drug: Soliris | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegcetacoplan, Drug: Soliris | Intervention Type: DRUG; Name: Pegcetacoplan; Assigned to Arm(s): Eculizumab, Pegcetacoplan | Intervention Type: DRUG; Name: Soliris; Assigned to Arm(s): Eculizumab, Pegcetacoplan
B: Arm Label: Lampalizumab Once in Every 4 Weeks (Q4W); Type: EXPERIMENTAL; Interventions: Drug: Lampalizumab | Arm Label: Lampalizumab Once in Every 6 Weeks (Q6W); Type: EXPERIMENTAL; Interventions: Drug: Lampalizumab | Arm Label: Sham Comparator; Type: SHAM_COMPARATOR; Interventions: Other: Sham | Intervention Type: DRUG; Name: Lampalizumab; Assigned to Arm(s): Lampalizumab Once in Every 4 Weeks (Q4W), Lampalizumab Once in Every 6 Weeks (Q6W) | Intervention Type: OTHER; Name: Sham; Assigned to Arm(s): Sham Comparator
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: oseltamivir + zanamivir | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oseltamivir + zanamivir's placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: oseltamivir's placebo + zanamivir | Intervention Type: DRUG; Name: oseltamivir + zanamivir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oseltamivir + zanamivir's placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: oseltamivir's placebo + zanamivir; Assigned to Arm(s): 3
D: Arm Label: FCFD4514S; Type: EXPERIMENTAL; Interventions: Drug: FCFD4514S | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Drug: sham | Intervention Type: DRUG; Name: FCFD4514S; Assigned to Arm(s): FCFD4514S | Intervention Type: DRUG; Name: sham; Assigned to Arm(s): sham

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
Brief Summary: This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Telmisartan, Bisoprolol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan, Bisoprolol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: NT-proBNP guided treatment group; Type: ACTIVE_COMPARATOR; Interventions: Device: NT-proBNP measurements | Arm Label: Clinically guided arm; Type: PLACEBO_COMPARATOR; Interventions: Device: NT-proBNP measurements | Intervention Type: DEVICE; Name: NT-proBNP measurements; Assigned to Arm(s): Clinically guided arm, NT-proBNP guided treatment group
C: Arm Label: SOC; Type: PLACEBO_COMPARATOR; Interventions: Other: Drug therapy for HF | Arm Label: NT-proBNP arm; Type: ACTIVE_COMPARATOR; Interventions: Other: NT-proBNP guided HF therapy | Intervention Type: OTHER; Name: Drug therapy for HF; Assigned to Arm(s): SOC | Intervention Type: OTHER; Name: NT-proBNP guided HF therapy; Assigned to Arm(s): NT-proBNP arm
D: Arm Label: Darapladib; Type: EXPERIMENTAL; Interventions: Drug: Darapladib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darapladib; Assigned to Arm(s): Darapladib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Saline Solution Versus Voluven®: A Controlled Study of Fluid Resuscitation in Severe Sepsis
Brief Summary: Fluid resuscitation of severe sepsis may consist of natural or artificial colloids or crystalloids. There is no evidence-based support for one type of fluid over another.

The investigators hypothesis is that fluid resuscitation with Voluven® is advantageous to normal saline solution to improve sublingual microcirculation.


Options:
A: Arm Label: Voluven® Arm; Type: EXPERIMENTAL; Interventions: Drug: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®" | Arm Label: 0.9 % NaCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9 % NaCl | Intervention Type: DRUG; Name: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®"; Assigned to Arm(s): Voluven® Arm | Intervention Type: DRUG; Name: 0.9 % NaCl; Assigned to Arm(s): 0.9 % NaCl
B: Arm Label: 1, Albumin and Crystalloids; Type: OTHER; Interventions: Other: Albumin and Crystalloids | Arm Label: 2, Crystalloids; Type: OTHER; Interventions: Other: Crystalloids | Intervention Type: OTHER; Name: Albumin and Crystalloids; Assigned to Arm(s): 1, Albumin and Crystalloids | Intervention Type: OTHER; Name: Crystalloids; Assigned to Arm(s): 2, Crystalloids
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 7.5% hypertonic saline/6% Dextran-70 (HSD) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: 7.5% hypertonic saline (HS) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% normal saline | Intervention Type: DRUG; Name: 7.5% hypertonic saline/6% Dextran-70 (HSD); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 7.5% hypertonic saline (HS); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: 0.9% normal saline; Assigned to Arm(s): 3
D: Arm Label: Voluven; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Voluven) | Arm Label: Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Saline) | Intervention Type: DRUG; Name: Resuscitation (Voluven); Assigned to Arm(s): Voluven | Intervention Type: DRUG; Name: Resuscitation (Saline); Assigned to Arm(s): Saline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Saline Solution Versus Voluven®: A Controlled Study of Fluid Resuscitation in Severe Sepsis
Brief Summary: Fluid resuscitation of severe sepsis may consist of natural or artificial colloids or crystalloids. There is no evidence-based support for one type of fluid over another.

The investigators hypothesis is that fluid resuscitation with Voluven® is advantageous to normal saline solution to improve sublingual microcirculation.


Options:
A: Arm Label: Voluven® Arm; Type: EXPERIMENTAL; Interventions: Drug: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®" | Arm Label: 0.9 % NaCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9 % NaCl | Intervention Type: DRUG; Name: 6 % Hydroxyethylstarch 130/0.4 = "Voluven®"; Assigned to Arm(s): Voluven® Arm | Intervention Type: DRUG; Name: 0.9 % NaCl; Assigned to Arm(s): 0.9 % NaCl
B: Arm Label: HES 130/0.4; Type: EXPERIMENTAL; Interventions: Drug: 6% Hydroxyethyl starch 130/0.4 | Arm Label: Ringer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringers acetate | Intervention Type: DRUG; Name: 6% Hydroxyethyl starch 130/0.4; Assigned to Arm(s): HES 130/0.4 | Intervention Type: DRUG; Name: Ringers acetate; Assigned to Arm(s): Ringer acetate
C: Intervention Type: DRUG; Name: HyperHAES vs. RA-solution/NaCl; Assigned to Arm(s): N/A
D: Arm Label: Voluven; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Voluven) | Arm Label: Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Resuscitation (Saline) | Intervention Type: DRUG; Name: Resuscitation (Voluven); Assigned to Arm(s): Voluven | Intervention Type: DRUG; Name: Resuscitation (Saline); Assigned to Arm(s): Saline

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China
Brief Summary: Comparative trials of urokinase (UK) for 12 hours（UK-12h）or 24 hours (UK-24h) have produced similar results in acute pulmonary thromboembolism (PTE) thrombolysis. It is unclear whether the infusion time can be reduced further. The aim of this study was to investigate the efficacy and safety of weight adjusted dosage of UK-2h (20 000 IU/Kg) regime with the Uk-12h regime in selected patients with PTE in Chinese population.


Options:
A: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Urokinase | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Urokinase | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 2
C: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: rt-PA | Arm Label: group 2; Type: EXPERIMENTAL; Interventions: Drug: rt-PA | Intervention Type: DRUG; Name: rt-PA; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: rt-PA; Assigned to Arm(s): group 2
D: Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China
Brief Summary: Comparative trials of urokinase (UK) for 12 hours（UK-12h）or 24 hours (UK-24h) have produced similar results in acute pulmonary thromboembolism (PTE) thrombolysis. It is unclear whether the infusion time can be reduced further. The aim of this study was to investigate the efficacy and safety of weight adjusted dosage of UK-2h (20 000 IU/Kg) regime with the Uk-12h regime in selected patients with PTE in Chinese population.


Options:
A: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: rt-PA | Arm Label: group 2; Type: EXPERIMENTAL; Interventions: Drug: rt-PA | Intervention Type: DRUG; Name: rt-PA; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: rt-PA; Assigned to Arm(s): group 2
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Urokinase | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Urokinase | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 2
C: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Drug: tenecteplase (group A) | Arm Label: group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo ( group B) | Intervention Type: DRUG; Name: placebo ( group B); Assigned to Arm(s): group B | Intervention Type: DRUG; Name: tenecteplase (group A); Assigned to Arm(s): group A
D: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Parent Mentors to Improve Asthma Care for Urban Minority Children
Brief Summary: Asthma disproportionately affects minorities, but few studies have evaluated interventions to improve asthma outcomes in minority children.The purpose of the study is to determine whether Parent Mentors (PMs) are more effective than traditional asthma care in reducing minority children's asthma morbidity, costs, and use of services, while increasing families' quality of life and parental self-efficacy.


Options:
A: Intervention Type: BEHAVIORAL; Name: Improved management of severe neonatal infections; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Using Parent Mentors to Improve Asthma Care for Urban Minority Children; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Zinc and ORS | Arm Label: 2; Type: OTHER; Interventions: Drug: ORS only | Intervention Type: DRUG; Name: Zinc and ORS; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ORS only; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Solar Water Disinfection (SODIS) | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Solar Water Disinfection (SODIS); Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Parent Mentors to Improve Asthma Care for Urban Minority Children
Brief Summary: Asthma disproportionately affects minorities, but few studies have evaluated interventions to improve asthma outcomes in minority children.The purpose of the study is to determine whether Parent Mentors (PMs) are more effective than traditional asthma care in reducing minority children's asthma morbidity, costs, and use of services, while increasing families' quality of life and parental self-efficacy.


Options:
A: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: structured support groups | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: structured support groups; Assigned to Arm(s): intervention
B: Intervention Type: BEHAVIORAL; Name: Using Parent Mentors to Improve Asthma Care for Urban Minority Children; Assigned to Arm(s): N/A
C: Arm Label: Care Notebook; Type: OTHER; Interventions: Behavioral: Care Notebook | Arm Label: Care Notebook + Parent Navigator; Type: EXPERIMENTAL; Interventions: Behavioral: Parent Navigator, Behavioral: Care Notebook | Intervention Type: BEHAVIORAL; Name: Parent Navigator; Assigned to Arm(s): Care Notebook + Parent Navigator | Intervention Type: BEHAVIORAL; Name: Care Notebook; Assigned to Arm(s): Care Notebook, Care Notebook + Parent Navigator
D: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: light support, Other: 3 preventive home visits by a nurse | Arm Label: UP Protocol; Type: EXPERIMENTAL; Interventions: Other: Case Manager, Other: 3 preventive home visits by a nurse | Arm Label: UP-TECH Protocol; Type: EXPERIMENTAL; Interventions: Other: Case Manager, Other: Assistive Technologies, Other: 3 preventive home visits by a nurse | Intervention Type: OTHER; Name: Case Manager; Assigned to Arm(s): UP Protocol, UP-TECH Protocol | Intervention Type: OTHER; Name: Assistive Technologies; Assigned to Arm(s): UP-TECH Protocol | Intervention Type: OTHER; Name: light support; Assigned to Arm(s): Usual Care | Intervention Type: OTHER; Name: 3 preventive home visits by a nurse; Assigned to Arm(s): UP Protocol, UP-TECH Protocol, Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Parent Mentors to Improve Asthma Care for Urban Minority Children
Brief Summary: Asthma disproportionately affects minorities, but few studies have evaluated interventions to improve asthma outcomes in minority children.The purpose of the study is to determine whether Parent Mentors (PMs) are more effective than traditional asthma care in reducing minority children's asthma morbidity, costs, and use of services, while increasing families' quality of life and parental self-efficacy.


Options:
A: Arm Label: mailed information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: mailed information | Arm Label: community health worker; Type: EXPERIMENTAL; Interventions: Behavioral: community health worker | Intervention Type: BEHAVIORAL; Name: community health worker; Assigned to Arm(s): community health worker | Intervention Type: BEHAVIORAL; Name: mailed information; Assigned to Arm(s): mailed information
B: Arm Label: Nurse group; Type: EXPERIMENTAL; Interventions: Behavioral: Self management education | Arm Label: Lay educator group; Type: EXPERIMENTAL; Interventions: Behavioral: Self management education | Intervention Type: BEHAVIORAL; Name: Self management education; Assigned to Arm(s): Lay educator group, Nurse group
C: Intervention Type: DEVICE; Name: electronic medication monitoring system; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: parent-adolescent communication and problem-solving skills; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Using Parent Mentors to Improve Asthma Care for Urban Minority Children; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using Parent Mentors to Improve Asthma Care for Urban Minority Children
Brief Summary: Asthma disproportionately affects minorities, but few studies have evaluated interventions to improve asthma outcomes in minority children.The purpose of the study is to determine whether Parent Mentors (PMs) are more effective than traditional asthma care in reducing minority children's asthma morbidity, costs, and use of services, while increasing families' quality of life and parental self-efficacy.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Asthma Communication Education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Asthma Education | Intervention Type: BEHAVIORAL; Name: Asthma Communication Education; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Standard Asthma Education; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Disease Management; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Disease Management + Educational Home Visits; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Using Parent Mentors to Improve Asthma Care for Urban Minority Children; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Home-based adherence monitoring; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISE CONTROL)
Brief Summary: Many cardiac patients requiring device (defibrillator or pacemaker) related surgery are on chronic oral anticoagulation therapy (usually coumadin). The risk of blood clot formation related to stopping oral anti-coagulant therapy is currently managed by using bridging heparin therapy in patients with moderate to high risk of blood clot formation. There is a substantial risk of bleeding in the pocket where the device is situated (pocket hematoma)related to bridging therapy. The purpose of this study is to compare the current standard of care of bridging with heparin to an experimental strategy of continuing coumadin therapy in higher risk patients undergoing device surgery, with the hypothesis being that the continued oral anti-coagulation group will have a lower pocket hematoma rate as compared to the bridging with heparin group.


Options:
A: Arm Label: Interrupted apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interrupted apixaban | Arm Label: Uninterrupted apixaban; Type: EXPERIMENTAL; Interventions: Drug: Uninterrupted apixaban | Intervention Type: DRUG; Name: Interrupted apixaban; Assigned to Arm(s): Interrupted apixaban | Intervention Type: DRUG; Name: Uninterrupted apixaban; Assigned to Arm(s): Uninterrupted apixaban
B: Arm Label: Continuous heparin infusion group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Continuous heparin infusion | Arm Label: Intermittent heparin infusion group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent heparin infusion | Intervention Type: DRUG; Name: Continuous heparin infusion; Assigned to Arm(s): Continuous heparin infusion group | Intervention Type: DRUG; Name: Intermittent heparin infusion; Assigned to Arm(s): Intermittent heparin infusion group
C: Arm Label: Bridging anti-coagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin or unfractionated heparin | Arm Label: Continued oral anti-coagulation; Type: EXPERIMENTAL; Interventions: Drug: Warfarin or coumadin | Intervention Type: DRUG; Name: low molecular weight heparin or unfractionated heparin; Assigned to Arm(s): Bridging anti-coagulation | Intervention Type: DRUG; Name: Warfarin or coumadin; Assigned to Arm(s): Continued oral anti-coagulation
D: Arm Label: Standard medical therapy group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Catheter ablation group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheter ablation | Intervention Type: PROCEDURE; Name: Catheter ablation; Assigned to Arm(s): Catheter ablation group

Answer: C